CC Exclusive Analysis
According to a recent article by New Beauty, Injectables are evolving fast. Thanks to rapid scientific advancements, the landscape of aesthetic medicine is changing, and 2025-2026 will usher in a wave of new products. Get ready for a next generation of injectables—from short-duration neurotoxins to next-generation fillers—designed to deliver faster, longer-lasting, and even more natural-looking results. Here’s a look at what’s coming soon to the syringe.
TrenibotE from Allergan
What is it?
TrenibotE, indicated for the treatment of moderate to severe glabellar lines, provides a differentiated clinical profile to offer patients an opportunity to experience a faster onset and shorter treatment duration as an introduction to a neurotoxin,” said Darin Messina, Ph.D., senior vice president, aesthetics R&D, AbbVie in the company’s FDA submission press release in April 2025. “TrenibotE has the potential to transform the aesthetic toxin treatment landscape for new patients interested in the facial aesthetics category.”
“New patients wanting to experience the aesthetic benefits of a neurotoxin cite “fear of looking unnatural” as a barrier to initiating neurotoxin use for aesthetic indications. If approved, TrenibotE will be the first serotype E neurotoxin offering patients the opportunity to experience a neurotoxin with rapid clinical effect for a shorter duration of time as a trial before getting treatment with BOTOX® Cosmetic.”
When will it be available?
The target goal for commercialization, according to New Beauty, is 2026.
Relfydess from Galderma
What is it?
“RelfydessTM is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.
“RelfydessTM is developed and manufactured by Galderma. It is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow’s feet.”
When will it be available?
It is currently under review by the U.S. FDA, and has been approved for use in Europe and several other countries.
Evolysse Sculpt from Evolus
What is it?
Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
“Evolysse™ Sculpt, the flagship brand in the Evolysse™ collection, targets the highest-value segment of today’s dermal filler market and is among the few products currently indicated for the mid-face area. Its strong performance reinforces our strategy to build a leading performance beauty company with a portfolio designed for today’s aesthetic consumer,” says David Moatazedi, President and Chief Executive Officer of Evolus.
When will it be available?
According to New Beauty, FDA approval is expected in the second half of 2026.
Saypha MagIQ from Obagi
What is it?
Saypha MagIQ is an injectable hyaluronic acid (HA) gel – the first intradermal filler product in the Obagi saypha® collection – FDA approved for commercial use in the U.S. market.
“Obagi saypha® MagIQ™ is powered by Croma’s U.S. pivotal study for nasolabial fold (NLF) correction including 270 patients and confirming non-inferiority versus the FDA approved control product, meeting the primary performance endpoint with key secondary endpoints further reinforcing its effectiveness and safety profile. The trial included all Fitzpatrick Skin Types demonstrating the product’s effectiveness and safety across a representative population.”
When will it be available?
U.S. launch is expected in 2026 with FDA approval obtained in 2025.
Leave a Reply